James Blair

Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO.

Santarus, Inc. operates as a biopharmaceutical company. The company was founded on December 6, 1996 and is headquartered in Bridgewater, NJ.

GeneOhm Sciences, Inc. develops molecular diagnostic products. It offers methicillin-resistant staphylococcus aureus (MRSA) Assay an in vitro diagnostic test for the direct detection of MRSA from a nasal specimen. The company was founded on 2001 and is headquartered in Franklin Lakes, NJ.

Verus Pharmaceuticals, Inc. was provided pediatric-oriented pharmaceutical products. The company was founded by David A. Socks, James Carroll Blair, Robert W. Keith, Cam L. Garner and David F. Hale in 2002 and was headquartered in San Diego, CA.

Benvenue Medical, Inc. engages int the provision and development of invasive systems for spine repair. It offers Kiva an implant solution for vertebral augmentation and a departure from balloon kyphoplasty, Blazer-C a vertebral augmentation system that utilizes a unique cannulated curved wire offering mechanical channel creation, and Luna a interbody implant that is delivered through a minimally-invasive cannula to the disc space and expands in-situ. The company was founded by Laurent B. Schaller in 2004 and is headquartered in Santa Clara, CA.

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C.

GenVault Corp. provides integration of biosample transport, storage and retrieval services. The firm also offers storage solutions for genomic medicine, discovery and identification applications. The company was founded by Mitchell D. Eggers and Michael E. Hogan in 2001 and is headquartered in Carlsbad, CA.

Volcano Corp. designs, develops and manufactures a broad suite of intravascular ultrasound products. The company was founded by Olav B. Bergheim and Samuel Ward Casscells and is headquartered in San Diego, CA.

IntegenX, Inc. develops rapid human DNA identification technology, next-gen sequencing library preparation, and DNA/RNA ambient temperature stability and storage products. The firm platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce products for DNA-based human identity testing and forensics and biodefense applications. The company was founded by Stevan Jovanovich, Dennis W. Harris, Richard A. Mathies in 2003 and is headquartered in Pleasanton, CA.

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.

OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA.

Meritage Pharma, Inc. develops prescription products for the treatment of gastrointestinal and atopic diseases. The company was founded by Cam L. Garner, Elaine M. Phillips and Adam K. Simpson in March 2008 and is headquartered in San Diego, CA.

Astute Medical, Inc. discovers and develops biomarkers for acute conditions and diseases. It develops protein biomarker-based diagnostics technology for high-risk medical conditions such as cerebrovascular injury, kidney injury, sepsis, abdominal pain, and acute coronary syndromes. The firm’s products include NephroCheck test and Astute140 meter kits. The company was founded by Christopher Richard Hibberd and Paul H. McPherson in 2007 and is headquartered in San Diego, CA.

Domain Associates LLC (Domain Associates) is a venture capital firm founded in 1985. The firm is headquartered in Princeton, New Jersey.

Part of Rothschild & Co. The private company is based in New York, NY. Continuation Holdings AG, Rothschild, Inc. provides investment banking and advisory services.

Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA.

Ansata Therapeutics, Inc. develops biopharmaceutical products. It develops and commercializes topical drugs for dermatologic indications. The company was founded by Brian A. Pollok in 2002 and is headquartered in La Jolla, CA.

Mallinckrodt Hospital Products, Inc. operates as a biopharmaceutical company, which develops and commercializes proprietary product candidates used in the hospital setting. The firm offers OFIRMEV (acetaminophen injection), a proprietary intravenous formulation of acetaminophen for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of fever. The company was founded by Theodore R. Schroeder, David A. Socks, and Cam L. Garner on May 26, 2004 and is headquartered in Hazelwood, MO.

ProteinSimple engages in the proprietary systems and consumables for protein analysis. Its products include simple plex, ice, simple western, micro-flow imaging, and single-cell western. The company was founded by Linda Cahill, Nancy Allbritton, Christopher Sims, Scott Lockard, and Jim Schlater in December 2000 and is headquartered in San Jose, CA.

Mountain Group Capital LLC (Mountain Group Capital) is a venture capital investment firm founded in 2002. The firm is headquartered in Nashville, Tennessee.

Sanford Burnham Prebys Medical Discovery Institute conducts and translates biological research programs. The firm offers tumor initiation and maintenance, cancer metabolism and signaling network, tumor microenvironment and cancer immunology, degenerative disease, development/aging/regeneration, immunity and pathogenesis, human genetic, cardiovascular metabolism, integrative metabolism, metabolism genomic control, bioinformatics and structural biology programs. The company was founded by William Fishman and Lillian Fishman in 1976 and is headquartered in La Jolla, CA.

CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand.

Helixis, Inc. develops a molecular diagnostic testing platform for use in diverse physical locations. The company was founded in 2007 by David Baltimore, Alex Dickinson, Matthew Johnston, George Maltezos & Axel Scherer and is headquartered in Carlsbad, CA.

Sequent Medical, Inc. operates as a medical device company. It develops catheter-based neurovascular technologies. The company was founded by Robert F. Rosenbluth and Brian J. Cox in August 2007 and is headquartered in Aliso Viejo, CA.

White, Weld & Co. LLC provides financial services. The private company is based in New York, NY.

F.S. Smithers & Co., Inc. provides financial services. The private company is based in New York, NY.

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Applied Proteomics, Inc. develops protein biomarkers for the healthcare and drug development sectors. It specializes in blood-based multiplex protein tests to help physicians, direct patients towards current standard-of-care patient management. The company was founded by David B. Agus and W. Daniel Hillis in May 2007 and is headquartered in San Diego, CA.

Gene Sciences, Inc. operates as a biotechnology company. The company was founded by Fei Yang and is headquartered in San Diego, CA.

Axial Therapeutics, Inc. provides biopharmaceuticals. It is harnessing the link between the human get microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders. The company was founded by Sarkis Mazmanian and David H. Donabedian and is headquartered in Boston, MA.

ChromaCode, Inc. develops software and manufactures laboratory instruments. It uses digital signal processing to improve clinical molecular analysis. The company was founded by Aditya Rajagopal, Alexander G. Dickinson, Axel Scherer, and Gregory J. Gosch in 2012 and is headquartered in Carlsbad, CA.

InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy.